Abiraterone, a CYP17 inhibitor, has shown to increase radiographic progression-free survival and OS, as well as delay the opiate use for both docetaxel-naïve and docetaxel-resistant mCRPC patients. 6 However, most of the patients included in these trials were from This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel-naïve patients than for docetaxel failures.
INTRODUCTION
Prostate cancer is the most common malignancy among men and second leading cause of cancer-related death in Western countries. 1 In the last decade, the incidence of prostate cancer has gradually increased in China and other Asian countries due to increased life expectancy, as well as the Westernized diet. 2 Moreover, the proportion of patients with metastatic prostate cancer is substantially higher in Asian countries compared to Western countries. 3 Androgen deprivation therapy is the backbone of metastatic prostate cancer management; nevertheless, almost all patients ultimately develop a more aggressive disease known as metastatic castration-resistant prostate cancer (mCRPC), which is accompanied by worsening of symptoms and poor outcomes. 4 In recent years, several novel therapeutic agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T have shown to improve overall survival (OS) in mCRPC patients.
photon emission computed tomography (ECT). During treatment, all patients received ongoing androgen deprivation therapy or had undergone prior bilateral orchiectomy. Serum PSA and testosterone levels were evaluated every month. Imaging studies were requested by the treating physician, based on increasing PSA values and/or new clinical signs or symptoms.
The following clinical and pathological characteristics were analyzed: patient's age at the time of abiraterone initiation, the Eastern Cooperative Oncology Group (ECOG) performance status, serum levels of PSA, hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and albumin (ALB), Gleason score and clinical stage at initial diagnosis, site and extent of metastatic disease, and based on types of previous hormonal therapeutic regimens.
Clinical endpoints were defined according to the Prostate Cancer Working Group 2 (PCWG2) criteria. 8 Confirmed PSA response was defined as a reduction in the PSA level from baseline by ≥50%, and maintained for ≥4 weeks. Maximal PSA response was defined as the maximal percentage decrease in PSA level from baseline. PSA progression-free survival was defined as the time interval from abiraterone initiation to first documented PSA progression (defined as a 25% increase in PSA from baseline or nadir, and by ≥2 ng ml −1 ). Clinical or radiographic progression-free survival was defined as the interval from abiraterone initiation to symptomatic progression (worsening diseaserelated symptoms or new cancer-related complications), radiographic progression (≥20% increase in the sum of the diameters of soft-tissue target lesions on CT scanning or ≥2 new bone lesions on bone scanning), or death, whichever occurred first. Overall survival (OS) was defined as the interval from abiraterone initiation to death from any cause.
This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (No. 050432-4-1212B). Before the initiation of this study, informed consent was obtained from each patient. All the methods were carried out in accordance with the approved guidelines.
Statistical analyses
The descriptive statistics were reported as medians with ranges for continuous variables and as populations and frequencies for categorical variables. The t-test (normal distribution data) and Mann-Whitney U test (nonnormal distribution data) were used to compare continuous variables. The Fisher's exact (small size sample) or Pearson's Chi-squared test were used to compare categorical variables. Survival was calculated using the Kaplan-Meier method with the Logrank test to assess differences between groups. Multivariate analysis of prognostic factors was performed using the Cox proportional-hazard model. Due to the limited number of patients, only variables that appeared to have a significant impact on survival by univariate analysis were included in the multivariate analysis. All statistical tests were done using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA); P < 0.05 was considered statistically significant.
RESULTS
The baseline clinicopathological characteristics of the patients are summarized in Table 1 . Among 146 mCRPC patients, 103 (70.5%) patients received abiraterone plus prednisone without prior exposure to docetaxel (docetaxel-naïve cohort) and 43 (29.5%) previously received chemotherapy with docetaxel (docetaxel-resistant cohort). The site of metastasis included as follows: bone (92.5%), lymph node (18.5%), liver (4.1%), lung (3.4%), brain (1.4%), and other soft tissue (1.4%). In addition, 121 patients developed multi-organ metastasis and none of the patients has previously received enzalutamide.
Patient characteristics, stratified by prior docetaxel use, are shown in Table 2 . The two cohorts were well balanced with respect to age, PSA level, ECOG status, Gleason score, tumor node metastasis (TNM) stage at diagnosis, duration of previous hormonal therapy, the extent of disease, and visceral metastatic rate. The albumin level was higher in the docetaxel-naïve cohort (P = 0.039), and no statistical difference was found in hemoglobin, ALP, and LDH level between the two cohorts.
Confirmed PSA response was observed in 48.6% (71/146) patients. Waterfall plots depicting PSA changes after initiation of abiraterone grouped according to previous docetaxel chemotherapy are presented in Supplementary Figure 1 . Significantly higher PSA response rates were found in docetaxel-naïve patients (54.4%, 56/103) compared to docetaxel-resistant patients (34.9%, 15/43) (P = 0.047, Table 3 ). Variable associated with confirmed PSA response are shown in Table 3 . Higher levels of ALP (P = 0.031) and LDH (P = 0.014), higher Gleason score of primary lesion (P = 0.001) and patients who previously received docetaxel chemotherapy (P = 0.047) were associated with a lower response to abiraterone ( Table 3) .
After a median (range) follow-up of 17 (6-50) months, 81 (55.5%) patients developed PSA progression, 68 (46.6%) patients developed clinical or radiographic progression and 52 (35.6%) patients died by the end of the Figure 1 , respectively. The median PSA progression-free survival among docetaxelresistant patients, was significantly shorter compared to docetaxel-naïve patients (7.7 vs 14.0 months, P = 0.005, Figure 1a) . Furthermore, the median clinical or radiographic progression-free survival among docetaxelresistant patients was significantly shorter compared to docetaxel-naïve patients (12.5 vs 17.0 months, P = 0.003, Figure 1b) . Moreover, the median OS among docetaxel-resistant patients was also significantly shorter than that of docetaxel-naïve patients (18.0 vs 27.0 months, P = 0.016, Figure 1c) . Table 4 lists the variables associated with OS in our patients. In univariate analyses, higher LDH, lower ALB, with visceral metastases and docetaxel-resistant were associated with shorter OS. In further multivariate analyses for OS, only lower ALB and visceral metastases were independent significant predictors for shorter OS.
DISCUSSION
In the last few years, some new treatment options for mCRPC have shown a survival benefit in clinic trials besides docetaxel: abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T. However, the prognosis for Chinese mCRPC patients treated with abiraterone plus prednisone remains unclear, since so far there have only been few studies on the topic including a large number of patients.
In the present study, we reported clinicopathological and survival data for 146 Chinese patients with mCRPC who were treated with abiraterone plus prednisone with or without prior exposure to docetaxel. Our data indicated that prognostic indicators were better in docetaxel-naïve group than in docetaxel-resistant group and lower ALB and visceral metastases are independent prognostic factors. The possible explanation is: (1) docetaxel-resistant patients have one less life-prolonging therapy available to them compared to docetaxelnaïve patients; (2) docetaxel is mostly used for symptomatic CRPC, whereas docetaxel-naïve patients treated with abiraterone might be asymptomatic. (3) the treatment of abiraterone has a slighter adverse reactions, more convenient treatment (oral) and more controlled therapeutic doses.
This study reported a large cohort of Chinese mCRPC patients who received abiraterone plus prednisone without prior exposure to docetaxel (docetaxel-naïve). 9 The efficacy of abiraterone group in our 103 docetaxel-naïve mCRPC patients was slightly inferior compared to those reported in COU-AA-302 trial. 10 In the COU-AA-302 trial, the confirmed PSA response rate was 62% and after long-term follow-up the median OS extended to 34.7 months in abiraterone group. 11 Yet, in the current study, the PSA response rate was 54.4% and the OS was 27.0 months in docetaxel-naïve patients. This difference can be explained by the following reason: more patients with poor performance were included in this study. Twelve of 103 (11.7%) patients had an ECOG performance status ≥2 ( Table 2) . Furthermore, no more new drug treatments available for follow-up treatment options for Chinese patients because of the country's new drug approval policy.
Although abiraterone has shown its life-prolonging efficacy in the treatment of mCRPC, the best sequential strategy for managing these patients remains unclear. Ryan et al. suggests that the top three successors treatment options in the COU-AA-302 trial after the failure of abiraterone were docetaxel (57%), cabazitaxel (18%), and enzalutamide (16%). 12 Further studies found that abirateronethen-enzalutamide strategy seems to be more advantageous in PSAprogression-free survival. 13, 14 In recent years, there have been many new changes in the treatment options for mCRPC. Currently, systemic treatment options for mCRPC include hormonal therapy (abiraterone, enzalutamide), chemotherapy (cabazitaxel, docetaxel), immunotherapy, and radionuclide therapy as well as bone-modifying agents and palliative or supportive measures. 15 Further, new drugs such as poly(adenosine Diphosphate-ribose) polymerase (PARP) inhibitors and PD-1 inhibitors, are under clinical investigation. Individualized management and information on how to select and sequence existing therapies began to appear. [16] [17] [18] [19] Early use of active agents even under castrate-sensitive conditions may change the clinical management of the disease according to LATITUDE and STAMPEDE trials. 20, 21 There are some limitations in this study. First, due to the inherent limitations of a single center retrospective cohort study, the previous treatments of our patients varied significantly in both docetaxel-resistant cohort and docetaxel-naïve cohort. These variations led to imbalance in baseline characteristics between the two cohorts, which could have influenced the final statistical results of the study. Yet, for the reason that docetaxel has been approved for mCRPC patients much earlier than abiraterone, in real clinical practice, mCRPC patients are always divided into docetaxel-resistant and docetaxel-naïve cohort regardless of other previous therapeutic regimens. Therefore, our data reflected the real everyday practice, and the obtained results are useful for clinical application. Second, the sample size was relatively small, especially in the docetaxel-resistant subgroup. Third, the median follow-up time was only 17 months, which is comparatively short. China or Asia need to have guidelines for the use of drugs for ethnic groups and populations. Considering that there is no authoritative guideline for the diagnosis and treatment of Chinese populations now, this study provides a reference for China to formulate relevant guidelines and further studies.
CONCLUSIONS
Previous randomized trials have shown that abiraterone plus prednisone is life-prolonging in both docetaxel-naïve and docetaxel-resistant patients. The present study, which included Chinese patients, is consistent with this practice. Higher PSA response rate and longer median OS were observed in the docetaxel-naïve subgroup, which suggested that abiraterone is more effective for docetaxel-naïve patients than for docetaxel failures for Chinese patients.
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